(S)-2-amino-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid hydrochloride | 253138-02-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (S)-2-amino-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid hydrochloride
• 英文别名: (S)-6-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-aminohexanoic acid hydrochloride；(2S)-2-amino-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid;hydrochloride
• CAS: 253138-02-2
• 化学式: C₂₁H₂₄N₂O₄*ClH
• 分子量: 404.894
• InChiKey: BSLVUEJQCVSAGF-FYZYNONXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.53
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  102
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-2-amino-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid hydrochloride 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 生成 9H-fluoren-9-ylmethyl N-[(5S)-5-cyano-5-[[6-[[3-[4-(cyanomethoxy)phenyl]-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carbonyl]amino]pentyl]carbamate
  参考文献：
  名称：

  Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

  摘要：

  In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is that the interaction between the plasmin inhibitors and key subsites in plasmin can be controlled by a spacer like hydantoin. The application of the novel chemotype is demonstrated by 1n and provides further evidence on the importance of hydantoin as the spacer. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.002
• 作为产物：
  描述：

  Fmoc-Lys(Boc)-OH*HCl 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 (S)-2-amino-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid hydrochloride
  参考文献：
  名称：

  A Bioorthogonal Dual Fluorogenic Probe for the Live‐Cell Monitoring of Nutrient Uptake by Mammalian Cells

  摘要：

  Cells rely heavily on the uptake of exogenous nutrients for survival, growth, and differentiation. Yet quantifying the uptake of small molecule nutrients at the single cell level is difficult. Here we present a new approach to studying the nutrient uptake in live single cells using Inverse Electron‐Demand Diels Alder (IEDDA) chemistry. We have modified carboxyfluorescein‐diacetate‐succinimidyl esters (CFSE)—a quenched fluorophore that can covalently react with proteins and is only turned on in the cytosol of a cell following esterase activity—with a tetrazine. This tetrazine serves as a second quencher for the pendant fluorophore. Upon reaction with nutrients modified with an electron‐rich or strained dienophile in an IEDDA reaction, this quenching group is destroyed, thereby enabling the probe to fluoresce. This has allowed us to monitor the uptake of a variety of dienophile‐containing nutrients in live primary immune cell populations using flow cytometry and live‐cell microscopy.

  DOI：

  10.1002/anie.202401733

文献信息

• Double-acylated GLP-1 derivatives
  申请人：Novo Nordisk A/S

  公开号：US10000542B2

  公开（公告）日：2018-06-19

  The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, which is connected at its CO—* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.

  本发明涉及一种GLP-1类似物的衍生物，该类似物包括第一个K残基和第二个K残基，分别位于与GLP-1（7-37）（SEQ ID NO：1）的位置26和37相对应的位置上，并且与GLP-1（7-37）相比最多有八个氨基酸变化；该衍生物包括通过连接剂连接到所述第一个和第二个K残基上的两个延长基团，其中所述延长基团选自Chem.1：HOOC-（CH2）x-CO-*和Chem.2：HOOC-C6H4-O-（ ）y-CO-*，其中x为8-16的整数范围内的整数，y为6-13的整数范围内的整数；连接剂包括Chem.3：* -NH-（ ）q-CH [（ ）w-NR1R2] -CO- *，它在其CO- *端连接到GLP-1类似物的第一个或第二个K残基的epsilon氨基基团上，其中q为0-5的整数范围内的整数，R1和R2独立地表示* -H或* -CH3，w为0-5的整数范围内的整数；或其药学上可接受的盐，酰胺或酯。本发明还涉及其在治疗和/或预防所有形式的糖尿病和相关疾病中的药物应用，以及相应的新型肽和连接剂中间体。这些衍生物具有高效、稳定、持久和适合口服给药的特点。
• [EN] BAKUCHIOL DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] DÉRIVÉ DE BAKUCHIOL, SON SEL PHARMACEUTIQUEMENT ACCEPTABLE, PROCÉDÉ DE PRÉPARATION CORRESPONDANT ET UTILISATION ASSOCIÉE<br/>[ZH] 补骨脂酚衍生物、其药学上可接受的盐及其制备方法和应用
  申请人：JIANGXI SHIMEI PHARMACEUTICAL CO LTD

  公开号：WO2022088091A1

  公开（公告）日：2022-05-05

  一种补骨脂酚衍生物、其药学上可接受的盐及其制备方法和应用，其中补骨脂酚衍生物具有式(I)所示结构，上述基于补骨脂酚的一系列两亲性抗菌化合物，具有较优的抗菌活性，且在实验室模拟的耐药性研究中能够克服细菌耐药性的产生。
• WO2024078586A1
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] ANTIBODY CONJUGATES SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF<br/>[FR] ANTICORPS CONJUGUÉS SPÉCIFIQUES POUR LA MUCINE-1 ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：SCHERER TECHNOLOGIES LLC R P

  公开号：WO2023009835A9

  公开（公告）日：2024-01-04

  [EN] The present disclosure provides antibody conjugates (e.g., antibody-drug conjugates (ADCs)) specific for MUC1. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. Also provided are compositions that include the ADC of the present disclosure, including in some instances, pharmaceutical compositions. In certain aspects, provided are methods of using the ADC that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of the ADC of the present disclosure.
  [FR] La présente invention concerne des anticorps conjugués (par exemple, des conjugués anticorps-médicament (ADC)) spécifiques pour la MUC1. L'invention concerne également des méthodes de production de ces conjugués, ainsi que des méthodes d'utilisation de ceux-ci. L'invention concerne en outre des compositions qui contiennent les ADC de la présente invention, notamment, dans certains cas, des compositions pharmaceutiques. Selon certains aspects, l'invention concerne des méthodes d'utilisation des ADC qui comprennent l'administration d'une quantité thérapeutiquement efficace des ADC de la présente invention à un individu atteint d'un trouble de la prolifération cellulaire.
• ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF
  申请人：[en]SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

  公开号：WO2023208216A1

  公开（公告）日：2023-11-02

  Provided is an antibody-drug conjugate and its preparation methods and use, and specifically is an antibody-drug conjugate for treating HER3-positive cancers. Provided is a fully human HER3 antibody, which has excellent binding activity to HER3-positive cells and can efficiently deliver drugs to HER3-positive cells. Provided is a drug-linker molecule coupled to the antibody, and the drug comprises a DNA topoisomerase inhibitor. The obtained antibody-drug conjugate has a better drug-to-antibody ratio, and has a good targeted killing effect on colon cancer, gastric cancer, breast cancer, and lung cancer (e.g., non-small cell lung cancer, specifically, lung adenocarcinoma). Provided is a preparation method for the antibody-drug conjugate and application of the antibody-drug conjugate in the treatment of a HER3-positive cancer.